Federal State Budgetary Educational Institution of Higher Education "South-Ural State Medical University" of the Ministry of Healthcare of the Russian Federation, 454092 Chelyabinsk, Russia.
Int J Mol Sci. 2022 Sep 5;23(17):10195. doi: 10.3390/ijms231710195.
Current data on the possible involvement of aging neutrophils in atherogenesis are limited. This study aimed to research the diagnostic value of aging neutrophils in their relation to subclinical atherosclerosis in statin-naïve patients without established atherosclerotic cardiovascular diseases (ASCVD).
The study was carried out on 151 statin-naïve patients aged 40-64 years old without ASCVD. All patients underwent duplex scanning of the carotid arteries, lower limb arteries and abdominal aorta. Phenotyping and differentiation of neutrophil subpopulations were performed through flow cytometry (Navios 6/2, Beckman Coulter, USA).
The number of CD62LCXCR4-neutrophils is known to be significantly higher in patients with subclinical atherosclerosis compared with patients without atherosclerosis ( = 0.006). An increase in the number of CD62LCXCR4-neutrophils above cut-off values makes it possible to predict atherosclerosis in at least one vascular bed with sensitivity of 35.4-50.5% and specificity of 80.0-92.1%, in two vascular beds with sensitivity of 44.7-84.4% and specificity of 80.8-33.3%.
In statin-naïve patients 40-64 years old without established ASCVD with subclinical atherosclerosis, there is an increase in circulating CD62LCXCR4-neutrophils. It was also concluded that the increase in the number of circulating CD62LCXCR4-neutrophils demonstrated moderate diagnostic efficiency (AUC 0.617-0.656) in relation to the detection of subclinical atherosclerosis, including polyvascular atherosclerosis.
目前关于衰老中性粒细胞在动脉粥样硬化形成中可能发挥作用的数据有限。本研究旨在研究在未经他汀类药物治疗且无明确动脉粥样硬化性心血管疾病（ASCVD）的他汀类药物初治患者中，衰老中性粒细胞与亚临床动脉粥样硬化之间的关系，并评估其诊断价值。
本研究纳入了 151 名年龄在 40-64 岁、未经他汀类药物治疗且无 ASCVD 的他汀类药物初治患者。所有患者均接受颈动脉、下肢动脉和腹主动脉的双功能超声检查。通过流式细胞术（Navios 6/2，Beckman Coulter，美国）对中性粒细胞亚群进行表型和分化分析。
与无动脉粥样硬化患者相比，亚临床动脉粥样硬化患者的 CD62LCXCR4-中性粒细胞数量明显更高（ = 0.006）。CD62LCXCR4-中性粒细胞数量超过临界值可预测至少一个血管床的动脉粥样硬化，其灵敏度为 35.4-50.5%，特异性为 80.0-92.1%；预测两个血管床的动脉粥样硬化，其灵敏度为 44.7-84.4%，特异性为 80.8-33.3%。
在无明确 ASCVD 的亚临床动脉粥样硬化的 40-64 岁他汀类药物初治患者中，循环 CD62LCXCR4-中性粒细胞数量增加。研究还表明，循环 CD62LCXCR4-中性粒细胞数量的增加在检测亚临床动脉粥样硬化（包括多血管粥样硬化）方面具有中等诊断效率（AUC 0.617-0.656）。
